| Chemotherapy-related anemia is anemia in patients with malignant tumors during chemotherapy. Age, tumor type, stage, duration, treatment, dose intensity, and during which occurred the occurrence of infection and so the impact of chemotherapy-related anemia, but the overall high incidence. Anemia caused by a variety of clinical symptoms, especially fatigue, seriously affecting the quality of life of patients with anemia caused by lack of oxygen also decreased susceptibility of tumor cells to chemotherapeutic drugs, seriously affecting the efficacy and prognosis. Blood transfusion and recombinant human erythropoietin hormone (rHuEPO) is the main treatment for the treatment of chemotherapy-related anemia. But its side effects, onset time and cost of treatment are limited to clinical applications. Therefore, to explore more effective treatment and drugs attracts the concern of clinicians.Chinese medicine theory that is closely related to the occurrence of cancer incidence and chemotherapy-related anemia with spleen and kidney dysfunction. The birth of the kidney, spleen, is acquired, the first, the lack of acquired lack of righteousness, the inability exorcism scattered evil, falling phlegm and plot into the chemotherapy drugs "fire with fire", but also hurt the body righteousness, spleen renal biochemistry, resulting in deficiency. Therefore, Chinese medicine will be chemotherapy-related anemia pathogenesis summarized as "spleen deficiency, and bleeding resistance. Therefore, we choose the "spleen and kidney, nourishing qi" effect of the compound A mortar as a test drug, the use of parallel control method to assess the compound A glue to improve the clinical efficacy of cancer chemotherapy-related anemia. In Beijing University of Traditional Chinese Medicine, Dongzhimen Hospital, Hematology and Oncology, and Beijing University of Chinese Medicine, East Hospital oncology research programs to collect valid cases92cases45cases in which treatment group and control group (n=47). The study results showed that:①peripheral blood picture aspects of the two groups after treatment HgB value compared to the treatment group was higher (P <0.05); no significant difference between two groups of RBC, WBC and PLT levels after treatment, but by the difference of RBC Statistical analysis found that compared with this group before treatment, the treatment group was higher, the difference was statistically significant (P<0.05).②of TCM Syndrome scoring treatment group compared with the previous reduced, effective in six cases (13.33%), effective36cases (80.0%),3cases (6.67%), the total efficiency of93.33%; markedly in the control group1cases (2.12%)effective in2cases (4.25%), ineffective in44cases (93.61%), the total efficiency of6.38%; TCM symptoms of the treatment group improved significantly better than the control group (P <0.05).③The of KPS score improvement, treatment group was markedly effective in7cases (15.56%), effective37cases (82.22%), and1case (2.22%), and97.78%; control group effective in2cases (4.26%), effective in40cases(85.11%), five cases (10.64%), the total efficiency of89.36%; the improvement of the quality of life, treatment is better than the control group (P<0.05). Collected another10cases using the group control method to observe the compound A mortar chemotherapy correlation between anemia EPO level findings, the EPO level changes in the, in patients taking the compound A mortar4weeks appears EPO level of improve (P<0.01), and Hgb level of changes, but slightly lagged behind the improvement of RBC level.Therefore, we believe that the compound A mortar can delay and improve chemotherapy-related anemia, alleviate clinical symptoms, improve patients’ quality of life, assist in the successful completion of chemotherapy. |
PDF Full Text Request